Pharmaceutical composition containing a tetrahydrofolic acid

A technology of tetrahydrofolate and composition, which is applied in the direction of drug combination, medical preparation containing active ingredients, pharmaceutical formula, etc.

Active Publication Date: 2009-07-15
BAYER IP GMBH
View PDF9 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The preparation of stable pharmaceutical compositions comprising low doses of tetrahydrofolate is a challenging task in itself, as stability issues are exacerbated when incorporated into pharmaceutical compositions at low concentrations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing a tetrahydrofolic acid
  • Pharmaceutical composition containing a tetrahydrofolic acid
  • Pharmaceutical composition containing a tetrahydrofolic acid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0098] Example 1 - Direct Compression; Microcrystalline Cellulose

[0099] 80 mg tablet cores with the following composition are prepared by direct compression:

[0100]

[0101] To test the stability of calcium 5-methyl-(6S)-tetrahydrofolate during storage under various conditions. The following stability data were obtained upon storage at 25°C / 60%RH and 40°C / 75%RH respectively (see Tables 1 and 2 below). Stability was tested in open and closed containers.

[0102] Table 1: Percentage of total degradation products

[0103]

[0104] Table 2: Amount (%)

[0105]

[0106] It can be seen that satisfactory stability of calcium 5-methyl-(6S)-tetrahydrofolate was obtained at 25°C even under conditions that allowed the tablets to be exposed to open air. In addition, satisfactory stability was obtained at 40°C (closed container), while 5-methyl-(6S)-tetrahydrofolate calcium was seen when the tablets were stored at 40°C while being exposed to open air. Significantly degr...

Embodiment 2

[0108] Embodiment 2-direct compression tablet; (Lactose Monohydrate / Cellulose Powder)

[0109] 80 mg tablet cores with the following composition are prepared by direct compression:

[0110]

[0111] To test the stability of calcium 5-methyl-(6S)-tetrahydrofolate during storage under various conditions. The following stability data were obtained upon storage at 25°C / 60%RH and 40°C / 75%RH respectively (see Tables 3 and 4 below). Stability was tested in open and closed containers.

[0112] Table 3: Sum of decomposition products (%)

[0113]

[0114] Table 4: percentage amount

[0115]

[0116] It can be seen that satisfactory stability of calcium 5-methyl-(6S)-tetrahydrofolate was obtained at 25°C. However, like Example 1, the dissolution rate of drospirenone was unsatisfactorily slow.

Embodiment 3

[0117] Embodiment 3 - direct compression tablet; (lactose monohydrate)

[0118] 80 mg tablet cores with the following composition are prepared by direct compression:

[0119]

[0120] The stability of calcium 5-methyl-(6S)-tetrahydrofolate was found to be unsatisfactory when stored at 25°C / 60%RH and 40°C / 75%RH, respectively. Like Examples 1 and 2, the dissolution rate of drospirenone was unsatisfactorily slow.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at least one pharmaceutical acceptable excipient or carrier. The compositions of the invention provide good stability of the tetrahydrofolic acid upon storage while still ensuring a fast and reliable release of the estrogen and the progestogen present in the composition.

Description

field of invention [0001] The present invention relates to solid pharmaceutical compositions, especially oral contraceptives, comprising tetrahydrofolate, such as calcium 5-methyl-(6S)-tetrahydrofolate. The composition provided by the present invention allows a good stability of said tetrahydrofolate in storage while still ensuring a fast and reliable release of the estrogen and progestogen present in said composition. Background of the invention [0002] In pregnant women, correction of low folate serum levels takes at least two months, whereas reserves last only as short as a few weeks. According to public health service recommendations, all women of potential pregnancy should therefore consume 400 μg / day of folic acid to reduce the risk of birth defects (MMWR Morb.Mortal.Wkly.Rep.1992;41(RR-14):1-7) . Folic acid supplementation immediately before stopping oral contraceptive use or immediately after a positive pregnancy test has already been obtained may not be sufficien...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/585A61K31/567A61K31/525A61P15/18
CPCA61K9/2018A61K9/2054A61P15/00A61P15/18A61P5/30A61P5/34A61K31/525A61K31/57A61K31/585A61K9/20A61K31/567A61K31/565
Inventor K·金
Owner BAYER IP GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap